Generation and characteristics of a novel “double-hit” high grade B-cell lymphoma cell line DH-My6 with MYC/IGH and BCL6/IGH gene arrangements and potential molecular targeted therapies
Metrics: PDF 854 views | HTML 1717 views | ?
Hiroaki Kikuchi1,2, Tomonori Higuchi1, Yumiko Hashida1, Ayuko Taniguchi3, Mikio Kamioka4, Takahiro Taguchi5, Akihito Yokoyama3, Ichiro Murakami6, Mikiya Fujieda2 and Masanori Daibata1
1Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
2Department of Pediatrics, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
3Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
4Department of Laboratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
5Department of Molecular and Cellular Biology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
6Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
Masanori Daibata, email: firstname.lastname@example.org
Keywords: double hit lymphoma; MYC; BCL6; PLK1; HDAC
Received: June 21, 2018 Accepted: August 10, 2018 Published: September 11, 2018
“Double-hit” lymphoma (DHL) is a high-grade B-cell lymphoma that harbors concurrent MYC and BCL2 or BCL6 rearrangements. Because cases of MYC/BCL6 DHL are uncommon, most reported conclusions have been based on cases of MYC/BCL2 DHL. Lack of experimental MYC/BCL6 DHL models continues to hinder the pathophysiologic and therapeutic investigations of this disorder. We herein describe a novel MYC/BCL6 DHL cell line, designated DH-My6, carrying both the MYC–IGH and BCL6–IGH fusion genes. Interruptions of MYC and BCL6 expressions using short interfering RNAs and chemical inhibitors led to significant attenuation of DH-My6 cell growth. Greater antitumor effects were found when the cells were treated with a combination of MYC and BCL6 inhibitors. Moreover, the PLK1 inhibitor volasertib and the HDAC inhibitor vorinostat synergized strongly when combined with the bromodomain inhibitor JQ1. DH-My6 is a new well-validated MYC/BCL6 DHL cell line that will provide a useful model for studies of the pathogenesis and therapeutics for the less common DHL tumor type. The rationale for approaches targeting both MYC and BCL6, and in combination with PLK1 or HDAC inhibitors for superior suppression of the aggressive MYC/BCL6 DHL warrants further in vivo testing in a preclinical model.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.